NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

Volver

Resultados 74 resultados LastUpdate Última actualización 18/01/2019 [15:04:00] pdf PDF




Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 3 nextPage   Mostrar por página


IDENTIFICATION OF CLASS I MHC ASSOCIATED GLYCOPEPTIDES AS TARGETS FOR CANCER IMMUNOTHERAPY

NºPublicación: US2019015494A1 17/01/2019

Solicitante:
UNIV OF VIRGINIA PATENT FOUNDATION [US]
THE UNIV OF BIRMINGHAM [GB]

Resumen de: US2019015494A1

Provided are compositions that include one or more peptides, wherein each peptide is at least 8 amino acids long and has an amino acid sequence as set forth in any of SEQ ID NOs: 1-45. Also provided are in vitro populations of dendritic cells that include the disclosed compositions, in vitro populations of CD8+ T cells capable of being activated upon being brought into contact with the disclosed populations of dendritic cells, antibodies or antibody-like molecules that specifically bind to complexes of MHC class I molecules and the disclosed peptides, methods for treating and/or preventing cancer such as leukemia using the disclosed compositions and/or populations, methods for making cancer vaccines using the disclosed compositions, methods for screening target peptides for inclusion in an immunotherapy composition, methods for determining a prognosis of a leukemia patient, and kits that include at least one of the disclosed peptides.



traducir


 

TREATMENT OF MYELODYSPLASTIC SYNDROMES WITH 2-O AND, OR 3-O DESULFATED HEPARINOIDS

NºPublicación: US2019015443A1 17/01/2019

Solicitante:
CANTEX PHARMACEUTICALS INC [US]

Resumen de: US2019015443A1

Methods are presented for treating cancers and hematopoietic stem cell disorders, comprising administering to a subject with a cancer or hematopoietic stem cell disorder who is receiving a treatment regimen, a heparin derivative capable of inhibiting, reducing, abrogating or otherwise interfering with the binding of CXCL12 to CXCR4, wherein the cancer or hematopoietic stem cell disorder is one in which interaction of CXCL12 with CXCR4 privileges the cancer or disordered HSCs against therapeutic intervention. In preferred embodiments, the heparin derivative is a substantially 2-O, 3-O-desulfated heparin derivative.



traducir


 

MULTICYCLIC COMPOUNDS AND USES THEREOF

NºPublicación: US2019016710A1 17/01/2019

Solicitante:
KARYOPHARM THERAPEUTICS INC [US]

Resumen de: US2019016710A1

The present invention relates to multicyclic compounds containing a urea or a guanidine moiety, or pharmaceutically acceptable salts or compositions thereof represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the multicyclic compounds. The invention also relates to a method for treating a disease or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, an inflammatory diseases or an immune system disease (e.g., a T-Cell mediated autoimmune disease) in a subject in need thereof. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof.



traducir


 

METHOD OF DIAGNOSING OR PROGNOSING EPITHELIAL OVARIAN CANCER

NºPublicación: US2019018016A1 17/01/2019

Solicitante:
IMMUNOVIA AB [SE]

Resumen de: US2019018016A1

The present invention provides a binding moiety which selectively binds to Sox11 protein and/or mRNA for imaging, diagnosis or prognosis of epithelial ovarian cancer (EOC). Optionally, the moiety is an antibody or antigen binding fragment thereof. Advantageously, moiety comprises a further, readily detectable moiety. The invention also provides methods of imaging EOC cells as well as methods of diagnosing or prognosing EOC in an individual. A further aspect of the present invention provides a method of identifying cells associated with EOC, the method comprising analysing the pattern of gene expression in a sample of cells to be tested and comparing it to the pattern of gene expression in a sample of known lymphomas cells



traducir


 

PHARMACEUTICAL COMPOSITIONS COMPRISING PHENYLAMINOPYRIMIDINE DERIVATIVE

NºPublicación: US2019015412A1 17/01/2019

Solicitante:
NATCO PHARMA LTD [IN]

Resumen de: US2019015412A1

An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically acceptable salts and polymorphs thereof, by dispersing in a polymer system in a final state of subdivision to enhance oral bioavailability. It also relates to processes for the preparation of such compositions and using those compositions for the treatment of Chronic Myeloid Leukemia and other tumors such as head and neck cancer, prostate cancer and the like.



traducir


 

A Composition, A Treatment Method and An Application Thereof

NºPublicación: US2019015458A1 17/01/2019

Solicitante:
BLUE ELEGANT BIOTECH CO LTD [CN]

Resumen de: US2019015458A1

The present invention relates to the field of treatment of tumor, and especially to a composition comprising a plasmodium, a treatment method and an application thereof. The composition of the present invention has therapeutic effects on colorectal carcinoma, lung carcinoma, breast carcinoma, gastric carcinoma and hepatic carcinoma etc., can inhibit the growth of tumor and prolong the life of the tumor patients, whereas has no therapeutic effect on melanoma and lymphoma; meanwhile, the present invention describes that the long-term plasmodium infection has better therapeutic effect on tumors, and the plasmodium immunotherapy of the present invention does not take the fever time as a course standard when treating tumors, but should be used to extend the duration of plasmodium infection as much as possible until the progression of tumors can be controlled under the premise of protecting the organ functions and life safety of the patients.



traducir


 

ADHERENT CANCER CELL LINE EXPRESSING A HEMATOLOGICAL TUMOR ANTIGEN

NºPublicación: US2019015493A1 17/01/2019

Solicitante:
PROMAB BIOTECHNOLOGIES INC [US]
FOREVERTEK BIOTECHNOLOGY CO LTD [CN]

Resumen de: US2019015493A1

The present invention relates to a transduced cancer cell line stably expressing a leukemia tumor antigen, wherein the cancer cell line is cervical cancer cells, breast cancer cells, ovarian cancer cells, pancreatic cancer cells, lung cancer cells, or glioblastoma cells. The transduced adherent cell line of the present invention is useful for many pre-clinical applications such as real time cytotoxicity assay or to test the effects of CAR-T cells that target the tumor antigen. The present invention is exemplified by Hela cell line stably expressing CD19.



traducir


 

Emetine Derivatives, Prodrugs Containing Same, And Methods Of Treating Conditions Using Same

NºPublicación: US2019016716A1 17/01/2019

Solicitante:
BAKARE OLADAPO [US]
DENMEADE SAMUEL RAY [US]
AKINBOYE EMMANUEL S [US]

Resumen de: US2019016716A1

Compounds are provided herein which are emetine derivatives that can be used as prodrugs which selectively undergo activation to release emetine in specific cellular conditions. In one aspect, a blocking group is incorporated onto the emetine molecule by the derivization of the N2′-position with moieties that can be selectively removed by hydrolysis in the cancer/tumor microenvironment. Such compounds are less cytotoxic than emetine and are substantially inactive in non-cancerous cells. In one aspect, the compounds described herein can be used for the treatment of metastatic and non-metastatic cancers, including, for example, breast cancer, prostate cancer, lung cancer, and leukemia.



traducir


 

PHARMACEUTICAL FORMULATIONS OF A BRUTON'S TYROSINE KINASE INHIBITOR

NºPublicación: US2019015340A1 17/01/2019

Solicitante:
PHARMACYCLICS LLC [US]

Resumen de: US2019015340A1

Described herein are pharmaceutical formulations of Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. Also disclosed are methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.



traducir


 

METHOD FOR PREDICTING SURVIVAL IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA

NºPublicación: WO2019011610A1 17/01/2019

Solicitante:
UNIV AUTONOMA DE BARCELONA UAB [ES]

Resumen de: WO2019011610A1

The invention relates to methods for predicting the clinical outcome of cancer patients, and in particular of acute lymphoblastic leukaemia (ALL) patients, in response to a therapy against ALL, preferably conventional chemotherapy, more preferably based on glucocorticoids, said methods based on the presence of particular polymorphism in genes coding for drug-metabolizing enzymes and apoptotic proteins. The invention relates as well to method for predicting the efficacy of a therapy based on conventional glucocorticoids as well as to method for personalized medicine in patients carrying said polymorphisms.



traducir


 

ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF

NºPublicación: WO2019014100A1 17/01/2019

Solicitante:
CELGENE CORP [US]
ALEXANDER MATTHEW D [US]
ARTMAN GERALD D III [US]
BRAY GORDON L [US]
CARMICHAEL JAMES [GB]
CARRANCIO SORAYA [US]
CATHERS BRIAN E [US]
CORREA MATTHEW D [US]
HANSEN JOSHUA [US]
HAVENS COURTNEY G [US]
KERCHER TIMOTHY S [US]
LOPEZ GIRONA ANTONIA [US]
LU XIAOLING [US]
MAN HON WAH [US]
NAGY MARK A [US]
NARLA RAMA K [US]
PICCOTTI JOSEPH R [US]
PIERCE DANIEL W [US]
TAVARES GRECO PAULA A [US]
WHITEFIELD BRANDON W [US]
WONG LILLY L [US]
ZOU NANFEI [US]

Resumen de: WO2019014100A1

Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.



traducir


 

TREATMENT OF B CELL MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI CD20 ANTIBODIES OR CHEMOTHERAPEUTICS

NºPublicación: WO2019011918A1 17/01/2019

Solicitante:
INT DRUG DEVELOPMENT BIOTECH [FR]

Resumen de: WO2019011918A1

The invention relates to novel combination therapies involving anti-CD19 antibodies for the treatment of cancer B cells expressing CD19. One preferred method is where the anti- CD19 proapoptotic MAb or a Fc optimized proapototic humanized MAb. In the methods of the present invention some anti-CD20 agents such as Rituxan®, or chemodrugs such as vincristine may be used in combitherapy. The methods of the present invention reduce the levels of B CD19 positive, more particularly in all diffuse large B cells lymphoma (DLBCL) subtypes and in Follicular lymphomas (FL).



traducir


 

INHIBITORS OF CREB-CBP INTERACTION FOR TREATMENT OF LEUKEMIA

NºPublicación: EP3426632A1 16/01/2019

Solicitante:
UNIV LELAND STANFORD JUNIOR [US]

Resumen de: WO2017156489A1

Compounds and methods are provided for inhibiting a CREB-CBP protein-protein interaction in a sample. In some cases, the method includes modulating transcription of CREB in a cell that overexpresses CREB. Also provided are methods of inhibiting the proliferation of a cancer cell. The subject CREB transcription inhibitor compounds include a substituted salicylamide or a prodrug thereof. Methods of alleviating symptoms associated with cancer (e.g., Acute Myeloid Leukemia (AML) or Acute Lymphomblastic Leukemia (ALL)) in a subject in need thereof are also provided. Pharmaceutical compositions including the subject compounds find use in treating cancer. The subject compounds may be formulated or provided to a subject in combination with a second agent, e.g. an anticancer agent.



traducir


 

ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF

NºPublicación: US2019008852A1 10/01/2019

Solicitante:
CELGENE CORP [US]

Resumen de: US2019008852A1

Provided herein is 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, and methods for treating, preventing or managing multiple myeloma using such compounds. Also provided are pharmaceutical compositions comprising the compounds, and methods of use of the compositions.



traducir


 

ANTI-NEOPLASTIC COMPOUNDS AND METHODS TARGETING QSOX1

NºPublicación: US2019008829A1 10/01/2019

Solicitante:
UNIV ARIZONA STATE [US]
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RES [US]

Resumen de: US2019008829A1

Compounds and methods involving inhibition of the enzymatic activity of QSOX1 (FIG. 13). The compounds and methods can be used in treatment of neoplastic cells, for example, to suppress tumor growth and invasion in a variety of cancers, including but not limited to myeloma and cancers of the breast, kidney, and pancreas.



traducir


 

USE OF RECOMBINANT CXCL16 AND INTERFERON-γ IN PREPARATION OF DRUG FOR INHIBITING PROLIFERATION OF DIFFUSE LARGE B-CELL LYMPHOMA CELLS

NºPublicación: WO2019006803A1 10/01/2019

Solicitante:
QIU BO [CN]
LIU FANG [CN]

Resumen de: WO2019006803A1

Disclosed is the use of a recombinant CXCL16 and interferon-γ in the preparation of a drug for inhibiting the proliferation of diffuse large B-cell lymphoma cells. In particular, the recombinant CXCL16 is used in combination with the interferon-γ in the preparation of a drug for inhibiting the proliferation of diffuse large B-cell lymphoma cells.



traducir


 

Novel Syringolin Analogues and Methods of Making and Using Same

NºPublicación: US2019010133A1 10/01/2019

Solicitante:
UNIV BROWN [US]

Resumen de: US2019010133A1

The present invention provides, in certain aspects, novel syringolin analogues, In certain embodiments, the compounds of the invention are proteasome inhibitors, In other embodiments, the compounds treat or prevent a cancer such as, but not limited to, leukemia in a subject.



traducir


 

Use of Ureidomustine (BO-1055) in Cancer Treatment

NºPublicación: US2019008808A1 10/01/2019

Solicitante:
ACAD SINICA [TW]
MEMORIAL SLOAN KETTERING CANCER CENTER [US]

Resumen de: US2019008808A1

Method of using ureidomustine (BO-1055), a water-soluble NDA cross-linking agent, in the treatment of a cancer, selected from the group consisting of various types of human leukemia [such as acute myeloid leukemia (ALL) and acute B Lymphoblastic leukemia (B-ALL)], lymphomas, small lung cell carcinoma (SCLC), sarcomas, and others.



traducir


 

COMPOSITION CONTAINING MONOACETYLDIACYLGLYCEROL COMPOUND AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING ASTHMA

NºPublicación: US2019008820A1 10/01/2019

Solicitante:
ENZYCHEM LIFESCIENCES CORP [KR]
KOREA RES INSTITUTE OF BIO SCIENCE AND BIOTECHNOLOGY [KR]

Resumen de: US2019008820A1

The present invention relates to a pharmaceutical composition containing a monoacetyldiacyiglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.



traducir


 

COMPOSITIONS AND METHODS FOR TREATING MULTIPLE MYELOMA

NºPublicación: US2019010120A1 10/01/2019

Solicitante:
BROAD INST INC [US]
MASSACHUSETTS GEN HOSPITAL [US]
HARVARD COLLEGE [US]

Resumen de: US2019010120A1

In one aspect, the present invention provides a method of inhibiting proliferation of a multiple myeloma cell, the method comprising contacting the cell with BRD9647, thereby inhibiting proliferation of the cell. In another aspect, the present invention provides a method of treating multiple myeloma in a pre-selected subject, the method comprising administering an effective amount of BRD9647 to the subject, wherein the subject is pre-selected by detecting a mutation in an AZIN1 polynucleotide or polypeptide relative to a reference in a biological sample obtained from the subject. In another aspect, the present invention provides a method of modulating benzoylation of an agent in a cell, the method comprising contacting the cell with BRD9647, thereby modulating benzoylation of an agent in the cell.



traducir


 

TETRAHYDRONAPHTHALENE DERIVATIVES THAT INHIBIT MCL-1 PROTEIN

NºPublicación: EP3424931A2 09/01/2019

Solicitante:
AMGEN INC [US]

Resumen de: EP3424931A2

Provided herein are intermediates that are useful in methods for producing myeloid cell leukemia 1 protein (Mcl-1) inhibitors of Formula (I), and methods for the preparation of the myeloid cell leukemia 1 protein (Mcl-1) inhibitors using the intermediates. The compounds of formula (I) and compositions comprising them may be used, for example, in the treatment of diseases or conditions, such as cancer.



traducir


 

Pharmaceutical compositions comprising phenylaminopyrimidine derivative

NºPublicación: GB2564262A 09/01/2019

Solicitante:
NATCO PHARMA LTD [IN]

Resumen de: GB2564262A

An oral pharmaceutical formulation containing an effective amount of NRC-AN-019 including its pharmaceutically acceptable salts and polymorphs thereof, by dispersing in a polymer system in a final state of subdivision to enhance oral bioavailability. It also relates to processes for the preparation of such compositions and using those compositions for the treatment of Chronic Myeloid Leukemia and other tumors such as head and neck cancer, prostate cancer and the like.



traducir


 

Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells

NºPublicación: AU2017262581A1 03/01/2019

Solicitante:
CELULARITY INC

Resumen de: AU2017262581A1

Provided herein are methods of treating acute myeloid leukemia (AML) and multiple myeloma (MM) by administering an effective amount of a cell population comprising natural killer cells, wherein the cell population comprising natural killer cells is produced by a three- stage method comprising culturing a population of hematopoietic stem or progenitor cells in media comprising stem cell mobilizing factors, e.g., three-stage methods of producing NK cells in media comprising stem cell mobilizing factors starting with hematopoietic stem or progenitor cells from cells of the placenta, for example, from placental perfusate (e.g., human placental perfusate) or other tissues, for example, umbilical cord blood or peripheral blood. Further provided herein are methods of using the NK cells produced by the three-stage methods provided herein to suppress the proliferation of acute myeloid leukemia cells. In certain embodiments, the NK cells produced by the three-stage methods described herein are used in combination with IL- 2.



traducir


 

METHODS OF DELAYING AND PREVENTING ACUTE MYELOID LEUKEMIA RELAPSE

NºPublicación: WO2019006133A1 03/01/2019

Solicitante:
IMMUNE PHARMACEUTICALS INC [US]

Resumen de: WO2019006133A1

Disclosed herein include methods of delaying and preventing acute myeloid leukemia (AML) relapse in patients with mutant nucleophosmin 1 (NPM1) by co-administration of histamine, or derivatives thereof, and interleukin-2 (IL-2). In some embodiments, an unexpected delay in and/or prevention of relapse results in a surprising increase in leukemia- free survival rate and overall survival rate.



traducir


 

COMPOSITIONS AND METHODS FOR IDENTIFYING AND TREATING RESISTANCE TO CTLA4 ANTAGONISTS IN LEUKEMIA

Nº publicación: WO2019005757A1 03/01/2019

Solicitante:
DANA FARBER CANCER INST INC [US]

Resumen de: WO2019005757A1

The present invention relates to compositions and methods for identifying and treating resistance to CTLA4 antagonists in neoplasia. In particular, the invention relates to compositions and methods for use in identifying and treating Ipilimumab resistant forms of leukemia.


traducir



 

Página1 de 3 nextPage Mostrar por página

Volver